Supplement encyclopedia

Moringa oleifera

Moringa oleifera is a plant whose leaves are eaten as food and used in oral supplements.

Double-check the conclusions and examine the sources before choosing a supplement.

Main conclusion

What it may offer

  • Two reviews of studies in adults with different health conditions did not give a clear answer on whether moringa helps reduce body weight or waist size. The evidence is very unreliable, and some studies used a plant blend or combined moringa with medicines.
  • In 16 young, active adults, a moringa leaf supplement showed no clear advantage in body fat percentage or exercise tests over six weeks. Such a small study may have missed a small benefit.

[1] [2] [3]

What was studied

  • Two reviews assessed body weight, weight adjusted for height and waist size in adults with different health conditions. The reviews may include overlapping studies, so they cannot be added together as independent trials.
  • The preparations differed: one study used a blend of three plants, while another gave a higher dose of atorvastatin together with moringa. The overall result therefore cannot be attributed to moringa alone.
  • In a separate small study, 16 young, physically active adults took a leaf supplement for six weeks. Body weight, body fat percentage, perceived exertion and physical test results were assessed.

[1] [2] [3]

Which forms were considered

  • The exercise study used the Moringa Arava leaf preparation: 310 mg twice daily for six weeks; the exact processing of the leaves was described ambiguously.
  • Leaf powder, extract, seeds, root and bark are different materials; when choosing a product, check the plant part, form and amount.

[1] [2]

How to get it from food

  • Moringa leaves, young pods and seeds are eaten as food; fresh or cooked leaves and powder differ in product form.
  • A serving of edible leaves, pods or seeds has not been established as equivalent to the studied leaf preparation. The weight of such a serving cannot be used to select a supplement dose.

[1]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
body weight, kgIn the study: body weight, kg. Before and after: 62.8 (10.7) → 63.0 (10.1) versus 65.5 (10.9) → 65.5 (10.9) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.Before and after: 62.8 (10.7) → 63.0 (10.1) versus 65.5 (10.9) → 65.5 (10.9) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.
2/4 LowLow confidence in the comparison for “body weight, kg”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.
11 trialEvaluation of the effects of commercial Moringa Oleifera supplement on physical fitness of young fit adults: A pilot study ↗16 physically active young adults, with 7 and 9 in the groups
  1. Evaluation of the effects of commercial Moringa Oleifera supplement on physical fitness of young fit adults: A pilot study ↗
BMIIn the study: BMI. Before and after: 23.3 (1.9) → 23.3 (1.9) versus 23.4 (3.5) → 23.3 (3.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.Before and after: 23.3 (1.9) → 23.3 (1.9) versus 23.4 (3.5) → 23.3 (3.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.
2/4 LowLow confidence in the comparison for “BMI”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.
11 trialEvaluation of the effects of commercial Moringa Oleifera supplement on physical fitness of young fit adults: A pilot study ↗16 physically active young adults, with 7 and 9 in the groups
  1. Evaluation of the effects of commercial Moringa Oleifera supplement on physical fitness of young fit adults: A pilot study ↗
body fat percentage, %In the study: body fat percentage, %. Before and after: 19.8 (6.8) → 20.8 (6.0) versus 20.9 (8.9) → 22.3 (9.2) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.Before and after: 19.8 (6.8) → 20.8 (6.0) versus 20.9 (8.9) → 22.3 (9.2) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.
2/4 LowLow confidence in the comparison for “body fat percentage, %”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.
11 trialEvaluation of the effects of commercial Moringa Oleifera supplement on physical fitness of young fit adults: A pilot study ↗16 physically active young adults, with 7 and 9 in the groups
  1. Evaluation of the effects of commercial Moringa Oleifera supplement on physical fitness of young fit adults: A pilot study ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Forms

Leaf powder, extract, seeds, root and bark are different materials; check the plant part, form and amount on the label.

Guidance for each goal

body weight, kg2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “body weight, kg”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: body weight, kg. Before and after: 62.8 (10.7) → 63.0 (10.1) versus 65.5 (10.9) → 65.5 (10.9) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: body weight, kg. Before and after: 62.8 (10.7) → 63.0 (10.1) versus 65.5 (10.9) → 65.5 (10.9) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

BMI2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “BMI”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: BMI. Before and after: 23.3 (1.9) → 23.3 (1.9) versus 23.4 (3.5) → 23.3 (3.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: BMI. Before and after: 23.3 (1.9) → 23.3 (1.9) versus 23.4 (3.5) → 23.3 (3.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

body fat percentage, %2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “body fat percentage, %”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: body fat percentage, %. Before and after: 19.8 (6.8) → 20.8 (6.0) versus 20.9 (8.9) → 22.3 (9.2) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: body fat percentage, %. Before and after: 19.8 (6.8) → 20.8 (6.0) versus 20.9 (8.9) → 22.3 (9.2) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

perceived exertion at minute 52/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “perceived exertion at minute 5”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: perceived exertion at minute 5. Before and after: 11.8 (4.9) → 11.8 (4.8) versus 12.5 (2.2) → 10.1 (3.7) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: perceived exertion at minute 5. Before and after: 11.8 (4.9) → 11.8 (4.8) versus 12.5 (2.2) → 10.1 (3.7) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

VO₂max; the unit for VO₂ is not given in the original table2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “VO₂max; the unit for VO₂ is not specified in the original table”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: VO₂max; the unit for VO₂ is not given in the original table. Before and after: 44.7 (8.2) → 41.6 (7.1) versus 41.0 (6.7) → 41.0 (6.8) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: VO₂max; the unit for VO₂ is not given in the original table. Before and after: 44.7 (8.2) → 41.6 (7.1) versus 41.0 (6.7) → 41.0 (6.8) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

perceived exertion at maximum2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “perceived exertion at maximum”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: perceived exertion at maximum. Before and after: 17.0 (3.9) → 16.7 (3.7) versus 17.7 (1.5) → 15.7 (3.7) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: perceived exertion at maximum. Before and after: 17.0 (3.9) → 16.7 (3.7) versus 17.7 (1.5) → 15.7 (3.7) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

mean Wingate power, W/kg2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “mean Wingate power, W/kg”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: mean Wingate power, W/kg. Before and after: 7.1 (1.5) → 6.3 (1.6) versus 7.1 (1.6) → 6.6 (8.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: mean Wingate power, W/kg. Before and after: 7.1 (1.5) → 6.3 (1.6) versus 7.1 (1.6) → 6.6 (8.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

peak Wingate power, W/kg2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison for “peak Wingate power, W/kg”: the randomized blinded pilot study is limited by unclear allocation details and a very small sample with variable measurements. The absence of a statistically significant difference does not prove equality; the conclusion concerns only the specified preparation and group.

In the study: peak Wingate power, W/kg. Before and after: 10.0 (3.4) → 8.5 (2.8) versus 9.7 (2.7) → 9.1 (1.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: peak Wingate power, W/kg. Before and after: 10.0 (3.4) → 8.5 (2.8) versus 9.7 (2.7) → 9.1 (1.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

Wingate fatigue indexNot assessedRead moreCollapse
Confidence
Not assessedAssessment of the fatigue index is impossible: the original control value “50/6” is ambiguous and affects the direction and magnitude of the comparison; replacing it with 50.6 would be a guess.

In the study: Wingate fatigue index. Before and after: 52.2 (11.5) → 47.7 (7.1) versus 50/6 (12.9) → 53.2 (4.6) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Study findings. In the study: Wingate fatigue index. Before and after: 52.2 (11.5) → 47.7 (7.1) versus 50/6 (12.9) → 53.2 (4.6) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.

Studied regimen310 mg twice daily, 620 mg/dayMoringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article
Duration and population6 weeks16 physically active young adults, with 7 and 9 in the groups

Comparison with dextrin placebo

body weight2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in “body weight” for a limited set of comparisons: the original review estimated a weighted mean difference of −0.06 kg (95% CI −1.60…1.48), p=0.938. Methodological limitations and the range of possible effects limit the conclusion. Lack of statistical significance does not prove absence of an effect. The mixture and differing concomitant therapies cannot be attributed to moringa alone.

In the study: body weight. Weighted mean difference −0,06 kg (95% CI −1,60…1,48), p=0,938.

Study findings. In the study: body weight. Weighted mean difference −0,06 kg (95% CI −1,60…1,48), p=0,938.

Studied regimen2,1–15 g/day in studies of this outcomeMoringa leaf preparations, including edible leaves; forms differ between studies
Duration and population30 days – 24 weeksDifferent groups of adults: Adults with type 2 diabetes; People living with HIV receiving antiretroviral therapy; Healthy adults. not established: the published groups may share a control group.

Comparison with placebo

BMI1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowVery low confidence in “BMI” for a limited set of comparisons: the original review estimated a weighted mean difference of +0.36 kg/m² (−0.55…1.28), p=0.435. Methodological limitations and the range of possible effects limit the conclusion. Lack of statistical significance does not prove absence of an effect. The mixture and differing concomitant therapies cannot be attributed to moringa alone.

In the study: BMI. Weighted mean difference +0,36 kg/m² (−0,55…1,28), p=0,435.

Study findings. In the study: BMI. Weighted mean difference +0,36 kg/m² (−0,55…1,28), p=0,435.

Studied regimen2–30 g/day in studies of this outcomeMoringa leaf preparations, including edible leaves; forms differ between studies
Duration and population30 days – 24 weeksDifferent groups of adults: Adults with hyperlipidemia; People living with HIV receiving antiretroviral therapy; Adults living with HIV; Healthy adults. not established: the published groups may share a control group.

Comparison with placebo or nutritional counselling; in Sarfraz, moringa 2 g + atorvastatin 40 mg versus placebo + atorvastatin 10 mg

body weight1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowVery low confidence in “body weight” for a limited set of comparisons: the original review estimate was SMD −0.70 (95% CI −1.81; 0.40). Methodological limitations, the range of possible effects and substantial heterogeneity limit the conclusion. Lack of statistical significance does not prove absence of an effect. The mixture and differing concomitant therapies cannot be attributed to moringa alone.

In the review: body weight. SMD −0,70 (95% CI −1,81; 0,40). A study of a blend of three plants was included.

Study findings. In the review: body weight. SMD −0,70 (95% CI −1,81; 0,40). A study of a blend of three plants was included.

Studied regimen900 mg/day of the blend and 1–15 g/day of leaf powderLeaf powder and a blend containing moringa, murraya and turmeric
Duration and population4 weeks – 6 monthsDifferent groups of adults: Adults with overweight; Adults living with HIV; Adults with prediabetes; Adults with newly diagnosed type 2 diabetes receiving no treatment. 439 in the intervention and control groups according to the review; the shared control group may have been counted more than once.

Comparison with Placebo and other control interventions from the original studies; specific combinations depend on the study

BMI1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowVery low confidence in “BMI” for a limited set of comparisons: the original review estimate was SMD −0.69 (95% CI −1.59; 0.22). Methodological limitations, the range of possible effects and substantial heterogeneity limit the conclusion. Lack of statistical significance does not prove absence of an effect. The mixture and differing concomitant therapies cannot be attributed to moringa alone.

In the review: BMI. SMD −0,69 (95% CI −1,59; 0,22). A study of a blend of three plants was included.

Study findings. In the review: BMI. SMD −0,69 (95% CI −1,59; 0,22). A study of a blend of three plants was included.

Studied regimen900 mg/day of the blend and 1–30 g/day of leaf powderLeaf powder and a blend containing moringa, murraya and turmeric
Duration and population45 days – 6 monthsDifferent groups of adults: Adults with overweight; Adults living with HIV; Adults with prediabetes; Women with type 2 diabetes; Adults with hyperlipidemia. 542 in the intervention and control groups according to the review; the shared control group may have been counted more than once.

Comparison with Placebo and other control interventions from the original studies; specific combinations depend on the study

waist circumference1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowVery low confidence in “waist circumference” for a limited set of comparisons: the original review estimate was SMD −0.18 (95% CI −1.53; 1.17). Methodological limitations, the range of possible effects and substantial heterogeneity limit the conclusion. Lack of statistical significance does not prove absence of an effect. The mixture and differing concomitant therapies cannot be attributed to moringa alone.

In the review: waist circumference. SMD −0,18 (95% CI −1,53; 1,17). A study of a blend of three plants was included.

Study findings. In the review: waist circumference. SMD −0,18 (95% CI −1,53; 1,17). A study of a blend of three plants was included.

Studied regimen900 mg/day of the blend and 1–10 g/day of leaf powderLeaf powder and a blend containing moringa, murraya and turmeric
Duration and population12 weeks – 4 monthsDifferent groups of adults: Adults with overweight; Adults with prediabetes; Women with type 2 diabetes. 260 in the intervention and control groups according to the review; the shared control group may have been counted more than once.

Comparison with Placebo and other control interventions from the original studies; specific combinations depend on the study

Safety and limitations

Isolated cases of anaphylaxis after leaves, Stevens–Johnson syndrome after food containing leaves and a severe skin reaction after powder have been described. Their frequency and causal relationship are unknown from isolated cases. Seek urgent medical help for signs of a severe allergic or skin reaction. The professional MSK section recommends avoiding moringa during pregnancy and breastfeeding; this is a precaution from the source, not an estimate of how often edible leaves cause harm. Short trials do not establish the frequency of rare reactions or the safety of long-term use of different preparations. In a small four-week study in adults with type 2 diabetes who were not taking glucose-lowering treatment, 25% of the 16 participants in the moringa leaf powder group reported temporary diarrhoea that resolved on its own. The study used 8 g/day. This is an observation from one small group, rather than an established frequency for all supplement users.

Moringa oleifera ↗ · Review of the Safety and Efficacy of Moringa oleifera ↗ · Effect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naïve Type 2 Diabetes Patients: A Randomized Placebo Controlled Study ↗

Interactions

WithEffectActionSource
CYP3A4 substrates; rifampicinIn laboratory experiments, moringa inhibited the CYP3A4 enzyme. In a separate animal study, it increased rifampicin bioavailability. The significance of these observations for humans is unknown.Before taking the supplement, discuss it with the prescribing doctor or a pharmacist.Moringa oleifera ↗
sitagliptinIn an animal model, long-term combined use reduced the glucose-lowering effect of sitagliptin; its clinical significance for humans is unknown.Discuss the supplement with your doctor before using it; do not change prescribed treatment on your own.Moringa oleifera ↗

Food sources

Here moringa is a plant material, rather than a defined nutrient; the weight of an edible plant part alone does not indicate the amount of the studied preparation.

Moringa leaves and young pods are eaten as food; this does not establish equivalence to concentrated supplements.

Moringa oleifera ↗

Moringa leaves Moringa oleifera leaves are eaten as food; powder that is mixed with liquid is also available. Powder and fresh or cooked leaves are different products.

Moringa oleifera ↗

Young pods Moringa pods are also eaten as food. They should not be equated with leaf powder.

Moringa oleifera ↗

Moringa seeds MSK separately mentions eating the seeds; these are a different plant part from leaves or pods.

Moringa oleifera ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Evaluation of the effects of commercial Moringa Oleifera supplement on physical fitness of young fit adults: A pilot study ↗randomized placebo-controlled trialbody weight, kg: body weight, kg BMI: BMI body fat percentage, %: body fat percentage, % perceived exertion at minute 5: perceived exertion at minute 5 VO₂max; the unit for VO₂ is not given in the original table: VO₂max; the unit for VO₂ is not given in the original table perceived exertion at maximum: perceived exertion at maximum mean Wingate power, W/kg: mean Wingate power, W/kg peak Wingate power, W/kg: peak Wingate power, W/kg Wingate fatigue index: Wingate fatigue indexbody weight, kg: 16 physically active young adults, with 7 and 9 in the groups BMI: 16 physically active young adults, with 7 and 9 in the groups body fat percentage, %: 16 physically active young adults, with 7 and 9 in the groups perceived exertion at minute 5: 16 physically active young adults, with 7 and 9 in the groups VO₂max; the unit for VO₂ is not given in the original table: 16 physically active young adults, with 7 and 9 in the groups perceived exertion at maximum: 16 physically active young adults, with 7 and 9 in the groups mean Wingate power, W/kg: 16 physically active young adults, with 7 and 9 in the groups peak Wingate power, W/kg: 16 physically active young adults, with 7 and 9 in the groups Wingate fatigue index: 16 physically active young adults, with 7 and 9 in the groupsbody weight, kg: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo BMI: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo body fat percentage, %: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo perceived exertion at minute 5: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo VO₂max; the unit for VO₂ is not given in the original table: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo perceived exertion at maximum: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo mean Wingate power, W/kg: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo peak Wingate power, W/kg: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebo Wingate fatigue index: Moringa Arava leaf preparation in powder-filled capsules; the exact processing is described ambiguously in the article; 310 mg twice daily, 620 mg/day; 6 weeks; comparison: dextrin placebobody weight, kg: In the study: body weight, kg. Before and after: 62.8 (10.7) → 63.0 (10.1) versus 65.5 (10.9) → 65.5 (10.9) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. BMI: In the study: BMI. Before and after: 23.3 (1.9) → 23.3 (1.9) versus 23.4 (3.5) → 23.3 (3.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. body fat percentage, %: In the study: body fat percentage, %. Before and after: 19.8 (6.8) → 20.8 (6.0) versus 20.9 (8.9) → 22.3 (9.2) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. perceived exertion at minute 5: In the study: perceived exertion at minute 5. Before and after: 11.8 (4.9) → 11.8 (4.8) versus 12.5 (2.2) → 10.1 (3.7) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. VO₂max; the unit for VO₂ is not given in the original table: In the study: VO₂max; the unit for VO₂ is not given in the original table. Before and after: 44.7 (8.2) → 41.6 (7.1) versus 41.0 (6.7) → 41.0 (6.8) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. perceived exertion at maximum: In the study: perceived exertion at maximum. Before and after: 17.0 (3.9) → 16.7 (3.7) versus 17.7 (1.5) → 15.7 (3.7) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. mean Wingate power, W/kg: In the study: mean Wingate power, W/kg. Before and after: 7.1 (1.5) → 6.3 (1.6) versus 7.1 (1.6) → 6.6 (8.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. peak Wingate power, W/kg: In the study: peak Wingate power, W/kg. Before and after: 10.0 (3.4) → 8.5 (2.8) versus 9.7 (2.7) → 9.1 (1.5) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided. Wingate fatigue index: In the study: Wingate fatigue index. Before and after: 52.2 (11.5) → 47.7 (7.1) versus 50/6 (12.9) → 53.2 (4.6) (means and SD as reported in the table). The authors reported no significant differences; separate p values and CIs were not provided.
The Effect of Moringa oleifera on Body Weight and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ↗systematic review and meta-analysis of randomized trialsbody weight: body weight BMI: BMIbody weight: Different groups of adults: Adults with type 2 diabetes; People living with HIV receiving antiretroviral therapy; Healthy adults. not established: the published groups may share a control group. BMI: Different groups of adults: Adults with hyperlipidemia; People living with HIV receiving antiretroviral therapy; Adults living with HIV; Healthy adults. not established: the published groups may share a control group.body weight: Moringa leaf preparations, including edible leaves; forms differ between studies; 2,1–15 g/day in studies of this outcome; 30 days – 24 weeks; comparison: placebo BMI: Moringa leaf preparations, including edible leaves; forms differ between studies; 2–30 g/day in studies of this outcome; 30 days – 24 weeks; comparison: placebo or nutritional counselling; in Sarfraz, moringa 2 g + atorvastatin 40 mg versus placebo + atorvastatin 10 mgbody weight: In the study: body weight. Weighted mean difference −0,06 kg (95% CI −1,60…1,48), p=0,938. BMI: In the study: BMI. Weighted mean difference +0,36 kg/m² (−0,55…1,28), p=0,435.